Thermo Fisher Scientific heads into its July 22 Q1 results with the stock recovering strongly but the analyst community still cutting numbers — a divergence worth watching closely.
The price action this week has been the most striking feature of the setup. TMO has gained 3% on the week to $516.62, recovering ground after a bruising April — the stock fell 8.6% the day after its last earnings print and shed another 6.8% over the following five days. The one-month gain of 9.3% suggests investors are willing to look past that pain. Close peer IQV has led the sector with a 7.7% weekly gain, while DHR and RGEN have added around 1-2%. BRKR has been the outlier, falling 2.4% on the week, suggesting the recovery in life science tools names is selective rather than wholesale.
The borrow market tells a distinctly uncrowded story. Short interest is tiny at 1.2% of the free float — and trending flat over the past month, down about 7% from its late-May peak. Availability is effectively unlimited, with borrow supply vastly exceeding current demand. The one wrinkle is cost to borrow, which has jumped 80% over the past week to 0.51%, its highest level since early June. That move is more of a technical fluctuation than a structural shift — at half a percent annualised, it remains firmly in "easy borrow" territory, and the ORTEX short score has barely moved, holding in a narrow range around 29.4 all month. Overall, borrow conditions are loose and short sellers are not a meaningful force here.
The Street is constructive but quietly scaling back expectations ahead of the July 22 print. Evercore ISI maintained its Outperform last Sunday but trimmed its target a fraction to $570. Bernstein reinstated coverage in late June at Market Perform with a $520 target — roughly where the stock trades now — while Piper Sandler initiated at Neutral in mid-June with a $510 target. Those neutral initiations bracket the current price and imply the Street sees limited near-term upside even as the consensus remains technically a "buy." The mean price target is $591, about 14% above current levels, but the recent drift in targets is clearly downward; HSBC cut from Buy to Hold in early June, slashing its target from $670 to $540. Bulls point to projected 5.4% compound growth in the life science solutions segment and an 8.5% EPS CAGR over four years. Bears counter with the persistent margin story — adjusted EBIT margins have fallen roughly 830 basis points since 2021, and gross margins remain well below their 2019 peak. The forward EPS growth rank is strong at the 88th percentile, but the analyst recommendation differential score is near the bottom of the range at just 6 out of 100, reflecting how divided opinion has become.
Options positioning has tilted modestly more defensive. The put/call ratio has climbed to 1.02, about one standard deviation above its 20-day average of 0.99. That is a mild elevated reading — nowhere near the 52-week high of 2.27 — but the direction has been consistent all week, with the PCR holding above 1.0 every session since June 29. Investors are adding a little more downside protection, not panicking.
With the prior earnings release delivering an 8.6% single-day drop and a 6.8% five-day follow-through, the July 22 print becomes the focal point — specifically whether management can signal a credible path back toward the margin levels that justified the stock's historical premium multiple.
See the live data behind this article on ORTEX.
Open TMO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
